Knowledge of CYP2C9 and VKORC1 genotype can improve dosing of warfarin.

被引：0
|
作者：
Kim, M.
Huang, S.
Frueh, F.
Rahman, A.
Burckart, G. J.
Thummel, K. E.
Lesko, L. J.
机构：
[1] Univ So Calif, US FDA, Silver Spring, MD USA
[2] Washington Univ, US FDA, Silver Spring, MD USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2007年 / 81卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S18 / S18
页数：1
相关论文
共 50 条
  • [31] Influence of CYP2C9 and VKORC1 Polymorphisms on Warfarin and Acenocoumarol in a Sample of Lebanese People
    Esmerian, Maria O.
    Mitri, Zahi
    Habbal, Mohammad-Zuheir
    Geryess, Eddy
    Zaatari, Ghazi
    Alam, Samir
    Skouri, Hadi N.
    Mahfouz, Rami A.
    Taher, Ali
    Zgheib, Nathalie K.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (10): : 1418 - 1428
  • [32] VKORC1 and CYP2C9 Genotypes are Predictors of Warfarin-Related Outcomes in Children
    Shaw, Kaitlyn
    Amstutz, Ursula
    Hildebrand, Claudette
    Rassekh, S. Rod
    Hosking, Martin
    Neville, Kathleen
    Leeder, J. Steven
    Hayden, Michael R.
    Ross, Colin J.
    Carleton, Bruce C.
    PEDIATRIC BLOOD & CANCER, 2014, 61 (06) : 1055 - 1062
  • [33] THE IMPACT OF CYP2C9 AND VKORC1 VARIANTS ON STABLE WARFARIN DOSE IN THE PEDIATRIC POPULATION
    Vear, Susan
    Ayers, Dan
    Stein, C. Michael
    Ho, Richard
    PEDIATRIC BLOOD & CANCER, 2013, 60 : S34 - S35
  • [34] Effect of VKORC1 and CYP2C9 polymorphisms on warfarin dose requirement in Bangladeshi population
    Chowdhury, Zahid Sadek
    Shahjin, Farah
    Akter, Farhana
    Ahmed, Maizbha Uddin
    Islam, Mohammad Safiqul
    Bin Sayeed, Muhammad Shandaat
    Islam, Reazul
    Hasnat, Abul
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 30 (02) : 341 - 346
  • [35] Comparison of assay systems for warfarin-related CYP2C9 and VKORC1 genotyping
    Maurice, Carleta B.
    Barua, Pankaj K.
    Simses, Diane
    Smith, Penny
    Howe, John G.
    Stack, Gary
    CLINICA CHIMICA ACTA, 2010, 411 (13-14) : 947 - 954
  • [36] DISTRIBUTION OF THE CYP2C9 AND VKORC1 RISK ALLELES FOR WARFARIN RESPONSE IN THE ISRAELI POPULATION
    Efrati, Edna
    Elkin, Hila
    Krivov, Norberto
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (09): : 1095 - 1095
  • [37] VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients
    G. Oner Ozgon
    T. Y. Langaee
    H. Feng
    N. Buyru
    T. Ulutin
    A. C. Hatemi
    A. Siva
    S. Saip
    J. A. Johnson
    European Journal of Clinical Pharmacology, 2008, 64 : 889 - 894
  • [38] VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients
    Ozgon, G. Oner
    Langaee, T. Y.
    Feng, H.
    Buyru, N.
    Ulutin, T.
    Hatemi, A. C.
    Siva, A.
    Saip, S.
    Johnson, J. A.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (09) : 889 - 894
  • [39] Relative contribution of VKORC1, CYP2C9, and INR response to warfarin stable dose
    Suarez-Kurtz, Guilherme
    Perini, Jamila A.
    Silva-Assuncao, Edimilson
    Struchiner, Claudio J.
    BLOOD, 2009, 113 (17) : 4125 - 4126
  • [40] Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes
    Wen, M-S
    Lee, M. T. M.
    Chen, J-J
    Chuang, H-P
    Lu, L-S
    Chen, C-H
    Lee, T-H
    Kuo, C-T
    Sun, F-M
    Chang, Y-J
    Kuan, P-L
    Chen, Y-F
    Charng, M-J
    Ray, C-Y
    Wu, J-Y
    Chen, Y-T
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (01) : 83 - 89
12345